SVB Wealth LLC Buys New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

SVB Wealth LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 77,353 shares of the biopharmaceutical company's stock, valued at approximately $7,145,000.

Other large investors have also recently bought and sold shares of the company. AMF Tjanstepension AB raised its stake in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company's stock valued at $33,645,000 after buying an additional 51,390 shares in the last quarter. Swedbank AB raised its stake in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock valued at $171,672,000 after buying an additional 189,622 shares in the last quarter. Diversify Wealth Management LLC raised its stake in shares of Gilead Sciences by 48.6% in the 3rd quarter. Diversify Wealth Management LLC now owns 6,115 shares of the biopharmaceutical company's stock valued at $533,000 after buying an additional 2,000 shares in the last quarter. JFS Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 404.7% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,034 shares of the biopharmaceutical company's stock valued at $171,000 after buying an additional 1,631 shares in the last quarter. Finally, Financial Advocates Investment Management raised its stake in shares of Gilead Sciences by 4.6% in the 3rd quarter. Financial Advocates Investment Management now owns 15,111 shares of the biopharmaceutical company's stock valued at $1,267,000 after buying an additional 665 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on GILD shares. Cantor Fitzgerald restated a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Wolfe Research started coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an "outperform" rating and a $110.00 price objective for the company. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Finally, Bank of America reaffirmed a "buy" rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $102.08.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $91.96, for a total transaction of $781,660.00. Following the completion of the transaction, the chief financial officer now directly owns 132,373 shares of the company's stock, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 293,356 shares of company stock worth $29,166,240. Company insiders own 0.16% of the company's stock.

Gilead Sciences Trading Up 1.5 %

Gilead Sciences stock traded up $1.68 during trading hours on Monday, reaching $115.99. 10,015,754 shares of the company's stock traded hands, compared to its average volume of 7,668,860. The firm has a market capitalization of $144.55 billion, a price-to-earnings ratio of 313.49, a PEG ratio of 0.71 and a beta of 0.18. The firm's 50 day moving average is $97.87 and its 200-day moving average is $90.45. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $117.16.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.72%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.